S16 Ep15: Six-Year CheckMate 9LA Data Reinforce Durable Survival in Metastatic NSCLC: With David Carbone, MD, PhD
In today’s episode, we spoke with David Carbone, MD, PhD. Dr Carbone is a professor of internal medicine at The Ohio State University, co-leader of the Translational Therapeutics Program and director of the Thoracic Oncology Center at the Ohio State University Comprehensive Cancer Center–James, as well as the Barbara J. Bonner Chair in Lung Cancer Research in Columbus.
In our exclusive interview, Dr Carbone discussed the 6-year data from the phase 3 CheckMate 9LA trial (NCT03215706), which not only reaffirmed the durability of benefit with nivolumab (Opdivo) plus ipilimumab (Yervoy) and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.